Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S Albain, William E Barlow, Steven Shak, Gabriel N Hortobagyi, Robert B Livingston, I-Tien Yeh, Peter Ravdin, Roberto Bugarini, Frederick L Baehner, Nancy E Davidson, George W Sledge, Eric P Winer, Clifford Hudis, James N Ingle, Edith A Perez, Kathleen I Pritchard, Lois Shepherd, Julie R Gralow, Carl Yoshizawa, D Craig Allred, C Kent Osborne, Daniel F Hayes
20100001
2010 Jan 1
Lancet Oncol
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Lancet Oncol. 2010 Jan;11(1):55-65, Kathy S Albain, William E Barlow, Steven Shak, Gabriel N Hortobagyi, Robert B Livingston, I-Tien Yeh, Peter Ravdin, Roberto Bugarini, Frederick L Baehner, Nancy E Davidson, George W Sledge, Eric P Winer, Clifford Hudis, James N Ingle, Edith A Perez, Kathleen I Pritchard, Lois Shepherd, Julie R Gralow, Carl Yoshizawa, D Craig Allred, C Kent Osborne, Daniel F Hayes
Background The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence. Methods The...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
